Climb Bio (CLYM) catalysts

Upcoming FDA decisions and readouts we track for Climb Bio, each with the filing that announced it.

Listed on — Nasdaq Catalysts tracked — 1 Rows last checked — 12 Sep 2026

FreeBioList tracks 1 upcoming catalyst for Climb Bio (CLYM, listed on Nasdaq). It concerns CLYM116 (budoprutug) (IgA nephropathy / autoimmune (CD19 antibody)).

First on the list: the Phase 2 readout for CLYM116 (budoprutug) (IgA nephropathy / autoimmune (CD19 antibody)), guided by the company to H1 2027.

The row links to an SEC filing (8-K or 6-K). It has been verified by a person reading the filing itself, most recently on 12 Sep 2026. The methodology page explains each status.

Background reading: Clinical trial phases explained: Phase 1 to Phase 4.

Ticker: CLYM
Next catalyst: H1 2027
Type: Phase 2 readout
Listed options: Yes

Company ▾	Drug ▾	Effect / indication	Next catalyst ▾	Phase / type ▾	Status ▾	Source	Options
Climb Bio CLYM · Nasdaq	CLYM116 (budoprutug)	IgA nephropathy / autoimmune (CD19 antibody)	H1 2027 company guidance	Phase 2 readout	Verified	8-K exhibit 99.1 ↗	Yes
Notes — Filing states: "Initial data anticipated in 1H 2027; designed to confirm integrated Phase 1 PK/PD modeling and support advancing Q12W regimen into Phase 3." Source: 8-K exhibit 99.1, filed 03 Sep 2026 · verified 12 Sep 2026

Companies working on related conditions

Allogene Therapeutics (ALLO)Autoimmune disease (allogeneic CD19/CD70 CAR-T); First-line large B-cell lymphoma consolidation
Jade Biosciences (JBIO)IgA nephropathy (APRIL antibody); Rheumatoid arthritis; Dermatomyositis
Vera Therapeutics (VERA)IgA nephropathy
Xencor (XNCR)Rheumatoid arthritis (CD20 x CD3); B-cell autoimmune disease (CD19 x CD3); Advanced clear cell renal cell carcinoma (ENPP3 x CD3); Ulcerative colitis (anti-TL1A
Zai Lab Ltd. (ZLAB)IgA nephropathy